Table 3.
Pooled mean differences of subjective patient-reported outcomes in short-duration trial (8 to 12 weeks) of pharmacotherapies for overactive bladder
| OAB-q Symptom Bother score | PPBC | |||||||
|---|---|---|---|---|---|---|---|---|
| No. of studies | Baseline (mean)a | Change from baseline | MD (95% CI; I2) | No. of studies | Baseline (mean)a | Change from baseline | MD (95% CI; I2) | |
| Mirabegron 50 mg + solifenacin 5 mg vs. solifenacin 5 mg | 4 | 55.37 | −28.77 vs. −23.81 | −5.02(−6.21, −3.82; I2 = 0%) | 4 | NR | −1.49 vs. −1.21 | −0.35 (−0.48, −0.23; I2 = 34%) |
| Mirabegron 50 mg + solifenacin 5 mg vs. mirabegron 50 mg | 3 | 55.37 | −29.40 vs. −23.89 | −6.58 (−8.15, −5.00; I2 = 0%) | 3 | NR | −1.49 vs. −1.25 | −0.30 (−0.40, −0.20; I2 = 0%) |
| Mirabegron 50 mg vs. solifenacin 5 mg | 3 | 58.03 | −26.62 vs. −28.16 | 1.60 (0.21, 3.00; I2 = 9%) | 4 | 4.79 | −1.40 vs. −1.45 | 0.01 (−0.11, 0.14; I2 = 50%) |
| Mirabegron 50 mg vs. tolterodine ER 4 mg | 3 | 44.4 | −17.16 vs. −16.52 | −0.45 (−1.75, 0.84; I2 = 0%) | 2 | NR | −1.0 vs. −1.0 | −0.02 (−0.15, 0.12; I2 = 0%) |
Note: bold indicates statistically significant
Abbreviations: CI, confidence interval; ER, extended release; IR, immediate release; MD, mean difference; NR, not reported; OAB-q, Overactive Bladder Questionnaire; PPBC, Patient Perception of Bladder Condition
aMean at baseline calculated for studies with available data